After posting strong fourth-quarter earnings, Strides Pharma Science Ltd founder and group chief executive Arun Kumar said the company’s fortunes "are now resurgent" thanks to a “major strategy reset” focused on growing US revenues and an exit from Australia.
US sales rocketed 181% to INR37.32bn ($53m) in the fiscal fourth-quarter of 2018-19 from the same year-ago period, while overall revenue jumped 24% to INR83.89bn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?